Mei Yu
Research Scientist
Northbrook,IL
Summary
Veteran Ph.D. Scientist well-versed in multi-OMICS data analytics and scientific computation. Detail-oriented and fruitful professional experienced in Immunology and Molecular Biology. Excellence in communication, collaboration and scientific writing.
Overview
12
12
years of professional experience
10
10
years of post-secondary education
Work History
Research Scientist
Blood Research Institute, Versiti Inc.
04.2018 - Current
- Established NGS platforms and analytic pipelines for SC-RNASeq, SC-VDJSeq, SC-CITESeq, ChIP-Seq, ATAC-Seq, microbiome 16s rRNA sequencing in the lab from scratch
- Extensively collaborated with other labs on bioinformatics: including Whole Exome Sequencing (WES), Copy Number Variant (CNV) and mutation and single nucleotide polymorphism (SNP) analysis for tumor samples.
- First-authored and co-authored in 11 high-profile scientific papers in top leading journals including PNAS, Blood, Nature Communications, Oncogenes.
Postdoctoral Fellow
Blood Research Institute
06.2012 - 02.2018
- Established NGS platform and analytic pipelines for RNA-Seq, Repertoire-Seq and SMART-Seq in the lab.
- Established unique animal model resembling clinical pathogenesis of Heparin-induced thrombocytopenia (HIT), the most common drug-induced, immune-mediated thrombocytopenia.
- First-authored and co-authored in 12 high-impact scientific papers in the most prominent journals in Immunology and Hematology, including Nature Communications, Blood, Science Advances, Journal of Immunology and Journal of Biological Chemistry.
Education
Ph.D. - Immunology And Molecular Biology
Nanjing Unversity
Nanjing, Jiangsu, China 09.2005 - 06.2011
Bachelor of Science - Physiology, Biology
Nanjing Unversity
Nanjing, Jiangsu, China 09.2001 - 06.2005
Accomplishments
- Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses. Oncogene (2023) First author, performed the Rep-Seq, RNA-Seq, WES and CNV analysis
- Cloned antibodies from patients with heparin-induced thrombocytopenia (HIT) provide new clues to HIT pathogenesis. Blood (2023) 3rd co-author, performed the Rep-Seq and motif analysis
- CXCR5+PD-1+ follicular helper CD8 T cells control B cell tolerance. Nat. Commun. (2019) 2nd co-author, performed the SC-RNASeq analysis
- Discrete roles and bifurcation of PTEN signaling and mTORC1-mediated anabolic metabolism underlie IL-7-driven B lymphopoiesis. Sci. Adv. (2018) 2nd co-author, designed and performed several critical experiments.
- Phospholipase Cγ pathway-dependent mTOR signalling controls IL-7-mediated early B cell development. Nat. Commun. (2017) 1st author, designed and performed the research, analyzed the results, and wrote the manuscript.
Timeline
Research Scientist
Blood Research Institute, Versiti Inc.
04.2018 - Current
Postdoctoral Fellow
Blood Research Institute
06.2012 - 02.2018
Ph.D. - Immunology And Molecular Biology
Nanjing Unversity
09.2005 - 06.2011
Bachelor of Science - Physiology, Biology
Nanjing Unversity
09.2001 - 06.2005